2 weeks Ago By Defense World Staff
Annovis Bio ( NYSE:ANVS – Get Free Report ) ‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $30.00 price objective on the stock.
HC Wainwright’s price objective suggests a potential upside of 297.88% from the company’s current price. ANVS has been the subject of a number of other research reports.
Maxim Group upgraded Annovis Bio from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research report on Friday, October 25th. EF Hutton Acquisition Co.
I raised shares of Annovis Bio to a “strong-buy” rating in a report on Tuesday, August 13th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.
com, the company has a consensus rating of “Buy” and a consensus price target of $32.17. Check Out Our Latest Report on ANVS Annovis Bio Stock Down 1.
4 % Annovis Bio ( NYSE:ANVS – Get Free Report ) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.
64) by ($0.33). Equities analysts anticipate that Annovis Bio will post -2.
53 earnings per share for the current year. Institutional Trading of Annovis Bio Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc.
boosted its holdings in shares of Annovis Bio by 6.1% during the first quarter. Vanguard Group Inc.
now owns 357,942 shares of the company’s stock worth $4,260,000 after purchasing an additional 20,588 shares during the last quarter. Cetera Advisors LLC acquired a new stake in Annovis Bio in the 1st quarter worth about $122,000. Greenwich Wealth Management LLC grew its holdings in Annovis Bio by 19.
9% in the 2nd quarter. Greenwich Wealth Management LLC now owns 15,075 shares of the company’s stock valued at $87,000 after buying an additional 2,500 shares during the period. XTX Topco Ltd acquired a new position in shares of Annovis Bio during the 2nd quarter valued at about $115,000.
Finally, Quest Partners LLC acquired a new position in shares of Annovis Bio during the 3rd quarter valued at about $371,000. 15.83% of the stock is owned by hedge funds and other institutional investors.
About Annovis Bio ( Get Free Report ) Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. Further Reading Five stocks we like better than Annovis Bio Energy and Oil Stocks Explained Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025 What does consumer price index measure? Is Tesla’s Valuation a Bubble or Backed by Real Growth? What Investors Need to Know About Upcoming IPOs Trucking Stocks Led the Pack Last Week: Can They Keep Rolling? Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.
com's FREE daily email newsletter ..
